Navigation Links
BioMarin to Present at the J.P. Morgan Healthcare Conference
Date:1/3/2012

NOVATO, Calif., Jan. 3, 2012 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 11:30 a.m. PT. 

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease; and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:

 Investors

MediaEugenia Shen

Bob Purcell BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267 


'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces IND for BMN-111 for Achondroplasia is Active
2. BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
3. Highlights from BioMarins Research & Development Day
4. BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority
5. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
6. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
7. BioMarin to Host a Research and Development Day on December 8th
8. BioMarin Announces Third Quarter 2011 Financial Results
9. BioMarin to Present at the UBS Global Life Sciences Conference
10. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
11. BioMarin to Present at the Baird Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... Inc. (Nasdaq: HOLX ) announced today ... quarter ended March 26, 2016.  GAAP diluted earnings ... non-GAAP diluted EPS of $0.47 increased 14.6%.  Revenue ... basis, and 6.3% on a constant currency basis.  ... highlighted by 14.6% growth in non-GAAP EPS," said ...
(Date:4/27/2016)... , April 27, 2016 ... accelerator (MR-linac) platform will be the focal point of ... of the European Society for Radiotherapy & Oncology, taking ... MR-linac integrates a state-of-the-art radiotherapy system and a high-field ... to clearly see the patient,s anatomy in real time. ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... 30, 2016 , ... Powerful tools of hypnosis, hypnotherapy ... What is hypnosis and hypnotherapy and why after centuries, it is now ... (chronic and acute), birthing processes and medical procedures, depression, anxiety, fear reactions, anxiety ...
(Date:4/30/2016)... (PRWEB) , ... April 30, ... ... by CBC News on April 4th, 2016 questioned the use of the ... to EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure ...
(Date:4/29/2016)... ... 30, 2016 , ... Mercy College is expanding its Graduate Business Programs to ... expanding due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe ...
(Date:4/29/2016)... ... 29, 2016 , ... Shamangelic Healing, Sedona Arizona's Premier ... Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness to ... the store is just one more way Shamangelic Healing supports people’s quest for ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
Breaking Medicine News(10 mins):